Literature DB >> 28150806

Dyslipidaemia: Small triumph for fenofibrate therapy in dyslipidaemia.

Robert S Rosenson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28150806     DOI： 10.1038/nrcardio.2017.11

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  8 in total

1.  Effects of combination lipid therapy in type 2 diabetes mellitus.

Authors:  Henry N Ginsberg; Marshall B Elam; Laura C Lovato; John R Crouse; Lawrence A Leiter; Peter Linz; William T Friedewald; John B Buse; Hertzel C Gerstein; Jeffrey Probstfield; Richard H Grimm; Faramarz Ismail-Beigi; J Thomas Bigger; David C Goff; William C Cushman; Denise G Simons-Morton; Robert P Byington
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

2.  Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.

Authors:  Marshall B Elam; Henry N Ginsberg; Laura C Lovato; Marshall Corson; Joseph Largay; Lawrence A Leiter; Carlos Lopez; Patrick J O'Connor; Mary Ellen Sweeney; Daniel Weiss; William T Friedewald; John B Buse; Hertzel C Gerstein; Jeffrey Probstfield; Richard Grimm; Faramarz Ismail-Beigi; David C Goff; Jerome L Fleg; Yves Rosenberg; Robert P Byington
Journal:  JAMA Cardiol       Date:  2017-04-01       Impact factor: 14.676

3.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Authors:  A Keech; R J Simes; P Barter; J Best; R Scott; M R Taskinen; P Forder; A Pillai; T Davis; P Glasziou; P Drury; Y A Kesäniemi; D Sullivan; D Hunt; P Colman; M d'Emden; M Whiting; C Ehnholm; M Laakso
Journal:  Lancet       Date:  2005-11-26       Impact factor: 79.321

Review 4.  Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease.

Authors:  Robert S Rosenson; Michael H Davidson; Benjamin J Hirsh; Sekar Kathiresan; Daniel Gaudet
Journal:  J Am Coll Cardiol       Date:  2014-12-16       Impact factor: 24.094

5.  Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

Authors:  Robert S Rosenson; David A Wolff; Anna L Huskin; Irene B Helenowski; Alfred W Rademaker
Journal:  Diabetes Care       Date:  2007-05-04       Impact factor: 19.112

6.  Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).

Authors:  Michael H Davidson; Robert S Rosenson; Kevin C Maki; Stephen J Nicholls; Christie M Ballantyne; Theodore Mazzone; Dawn M Carlson; Laura A Williams; Maureen T Kelly; Heidi S Camp; Aditya Lele; James C Stolzenbach
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-04-17       Impact factor: 8.311

Review 7.  Interpretation of the evidence for the efficacy and safety of statin therapy.

Authors:  Rory Collins; Christina Reith; Jonathan Emberson; Jane Armitage; Colin Baigent; Lisa Blackwell; Roger Blumenthal; John Danesh; George Davey Smith; David DeMets; Stephen Evans; Malcolm Law; Stephen MacMahon; Seth Martin; Bruce Neal; Neil Poulter; David Preiss; Paul Ridker; Ian Roberts; Anthony Rodgers; Peter Sandercock; Kenneth Schulz; Peter Sever; John Simes; Liam Smeeth; Nicholas Wald; Salim Yusuf; Richard Peto
Journal:  Lancet       Date:  2016-09-08       Impact factor: 79.321

8.  Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.

Authors:  B Staels; N Vu-Dac; V A Kosykh; R Saladin; J C Fruchart; J Dallongeville; J Auwerx
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.